Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O. Burst Edition: FDA approvals of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer, and Nubeqa (darolutamide) in combination with docetaxel for metastatic hormone-sensitive prostate cancer

07 Sep 2022

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
šŸ—³ļø Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.